ZBH stock: buy or sell?

ZBH stock price: $146.78 1.21% At close on November 15th, 2019

Updated on:
November 15th, 2019

5

Shares of Zimmer Biomet closed yesterday at $146.78 after topping to a new all time high ($147.24) and appreciated a beatiful 1.21%.

Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Should I buy ZBH stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

These 2 buy setups are elegible for Zimmer Biomet stock right now:

Buy setupElegible
New all-time highYes
New 52 week highYes
Price crossing up 200d MANo
100d MA crossing up 200d MANo

Is Zimmer Biomet stock a buy?

Financial institutions and banks post stock ratings everyday. At Stocks2.com, we detected 15 ratings published for ZBH stock in the last month.

The general sentiment of these ratings is bullish for ZBH stock, with 11 positive ratings.
Is ZBH a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-9-9Wells Fargo & Con/aOutperform
2019-9-9Wells Fargo & Con/aOutperform
2019-9-18Needham & Company LLCn/aBuy
2019-9-18Canaccord GenuityHoldBuy
2019-9-16BTIG Researchn/aHold
2019-8-2Citigroupn/aBuy
2019-8-12ArgusHoldBuy
2019-7-30BarclaysUnderweightEqual Weight
2019-7-29Wells Fargo & Con/aOutperform
2019-7-29Robert W. BairdNeutralOutperform
2019-7-29Raymond Jamesn/aOutperform
2019-7-29Morgan Stanleyn/aOverweight
2019-7-29Jefferies Financial Groupn/aBuy
2019-7-29Credit Suisse Groupn/aUnderperform
2019-6-11Sanford C. BernsteinUnderperformMarket Perform

ZBH stock analysis

Daily outlook

Zimmer Biomet appreciated 1.21% to $146.78 after reaching all time highs yesterday.

After topping to all time highs yesterday, Zimmer Biomet appreciated 1.21% to $146.78. Since July when ZBH stock price broke up the SMA200d line, it gained $29.18 (24.81%). Since last August when SMA50d and SMA100d crossed up, ZBH price gained $8.09 per share (5.83%).

ZBH stock chart (daily)

Weekly outlook

Zimmer Biomet ended this week at $146.78 after marking a new all time high ($147.24) and raised a nice 1.93%. Counting this, it's been 3 green weeks in a row, gaining $12.71 or 9.24%. Late September ZBH plunged a frightening -5.70% in just one week.

ZBH shows a strong mid-term uptrend with several rising tops and rising bottoms. Since its last bottom late September, ZBH climbed unceasignly breaking out to new all time highs. Since mid June when ZBH stock price broke up the SMA40w line, it gained $29.78 (25.45%). Since SMA20d and SMA40w crossed up by mid May, ZBH price climbed $25.28 per share (20.81%).

ZBH stock chart (weekly)

ZBH stock price history

ZBH IPO was on July 25th, 2001 at $27.48 per share1. Since then, ZBH stock grew a 434.10%, with a yearly average of 24.10%. If you had invested $1,000 in ZBH stock in 2001, it would worth $4,341.00 today.

1: Adjusted price after possible price splits or reverse-splits.

ZBH stock historical price chart

ZBH stock reached all-time highs yesterday with a price of $147.24.

ZBH stock price target is $153.50

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' ZBH stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we found 12 price forecasts for Zimmer Biomet stock:
ZBH stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-9-9Wells Fargo & CoReiterates$150.00$158.005.3%
2019-9-9Wells Fargo & CoRaises Target$150.00$158.005.3%
2019-9-18Needham & Company LLCReiteratesn/a$170.00-
2019-9-18Canaccord GenuityUpgrades$137.00$167.0021.9%
2019-8-2CitigroupRaises Target$146.00$158.008.2%
2019-7-30BarclaysUpgrades$117.00$140.0019.7%
2019-7-29Wells Fargo & CoRaises Target$143.00$150.004.9%
2019-7-29Robert W. BairdUpgrades$132.00$154.0016.7%
2019-7-29Raymond JamesRaises Target$145.00$150.003.4%
2019-7-29Morgan StanleyRaises Target$143.00$150.004.9%
2019-7-29Jefferies Financial GroupRaises Target$150.00$167.0011.3%
2019-7-29Credit Suisse GroupReiterates$101.00$120.0018.8%
(in average)$137.60$153.5012.0%
Moving in a range from $170.00 and $120.00, the price prediction for ZBH stock is $153.50. In average, analysts' outlook on ZBH price forecast is positive, increasing the prediction by a 12.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

After publishing its last earnings report on April, Zimmer Biomet . Unfortunately, reported EPS is not yet available in our database.
ZBH earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q2-n/a1.63n/a
2017-Q32017-11-011.741.72-1.1%
2017-Q42018-01-302.12.10.0%
2018-Q12018-04-261.871.912.1%
2018-Q22018-07-271.881.922.1%
2018-Q32018-10-261.61.631.9%
2018-Q42019-02-012.182.180.0%
2019-Q12019-04-241.87n/an/a
2019-Q2-n/an/an/a
2019-Q3-n/an/an/a

Annual financial results

In 2018, Zimmer Biomet annual sales stepped up a slightly good 1.66% to $7,932.90 M USD from $7,803.30 marked in 2017. When comparing 2018 vs 2017, by contrast, profit margin (that is, the net income divided by revenues) collapsed a -28.02% to -4.78%.

To have an up to date view of the financial situation of Zimmer Biomet, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2019-Q1 that can be compared to 2018 fiscal year results. Annual Zimmer Biomet TTM sales up to March 2019 were $7,890.80 and earnings were $-307.80 million dollars. If we compare this TTM figures with the last reported annuality, we can review Zimmer Biomet business evolution since December 2018: Annual revenues up to March, compared to lastest yearly report, remained steady a tight -0.53%. Likewise, profit margin (net income/sales) stayed steady at -4.78%.

ZBH annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$4,620 M-$761 M16.5%-
2014$4,673 M1.15%$720 M15.4%-5.37%
2015$5,998 M28.34%$147 M2.5%-79.59%
2016$7,684 M28.11%$306 M4.0%108.10%
2017$7,803 M1.55%$1,814 M23.2%492.94%
2018$7,933 M1.66%$-379.20 M-4.8%-120.91%
TTM $7,891 M-0.53%$-307.80 M-3.9%-18.83%

Quarterly financial results

Zimmer Biomet posted $1,975.50 million in sales for 2019-Q1, a -4.61% decline compared to previous quarter. Reported quarter income marked $246.10 M with a profit margin of 12.46%. Profit margin climbed a 55.97% compared to previous quarter when profit margin was -43.51%. When comparing revenues to same quarter last year, Zimmer Biomet sales marked an unpleasant drop down and declined a -2.09%.
ZBH quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q2$1,950 M-$184.20 M9.4%-
2017-Q3$1,820 M-6.67%$98.80 M5.4%-46.36%
2017-Q4$2,089 M14.79%$1,231.40 M58.9%1,146.36%
2018-Q1$2,018 M-3.42%$174.70 M8.7%-85.81%
2018-Q2$2,008 M-0.50%$185.00 M9.2%5.90%
2018-Q3$1,837 M-8.51%$162.20 M8.8%-12.32%
2018-Q4$2,071 M12.76%$-901.10 M-43.5%-655.55%
2019-Q1$1,976 M-4.61%$246.10 M12.5%-127.31%

Zimmer Biomet ownership

When you are planning to buy shares of a company, it's worth to overview its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Zimmer Biomet, 0.24% of all outstanding shares are owned by its staff.

Bearish positions for ZBH stock account 0.00%, no big difference from last month.

For a better context understanding, the following table shows ownership data compared to other related companies:

ZBHCNMDGMEDJNJNUVA
Market cap$30.1 B$3.2 B$4.2 B$354.9 B$3.8 B
Total shares205.3 M28.4 M77.0 M2,630.0 M52.1 M
Float shares204.8 M27.7 M75.8 M2,630.0 M51.6 M
  - Institutional holdings (%)91.8%97.5%92.4%69.2%112.1%
  - Insider holdings (%)0.2%1.8%3.6%0.1%0.7%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

ZBH summary

Friday, November 15th, 2019
Open$145.39
Close$146.78
Day range$144.54 - $147.24
Previous close$145.03
Session gain1.21%
Average true range$2.90
50d mov avg$138.05
100d mov avg$134.17
200d mov avg$127.78
Daily pattern
Weekly pattern lb03c

Zimmer Biomet performance

To better understand Zimmer Biomet performance you must compare its gains with other related stocks in same sector or industry. For Zimmer Biomet, the comparison is made against CONMED, Globus Medical, , NuVasive, RTI Surgical, Smith & Nephew SNATS, Stryker and Wright Medical.
Stock3m6m12m
ZBHZimmer Biomet7.32%26.57%26.41%
CNMDCONMED19.15%41.29%66.38%
GMEDGlobus Medical10.43%28.97%6.14%
JNJ3.50%-1.24%-5.02%
NUVANuVasive15.14%20.32%19.17%
RTIXRTI Surgical-36.25%-56.42%-55.02%
SNNSmith & Nephew SN...-6.17%4.22%19.89%
SYKStryker-4.73%12.56%21.12%
WMGIWright Medical38.87%-7.29%-0.10%

Zimmer Biomet competitors

One check before investing in any stock is to have a look a list of its competitors, in this case for Zimmer Biomet. We picked 8 companies as Zimmer Biomet competitors as they are in the same industry or have similar market objectives.

Latest ZBH stock news